Recombinant antigens

HBeAg
for Hepatitis B virus (HBV)

The “e” antigen (HBeAg) is formed by the pre-core protein ORF that will result in the secretion of a heterogeneous population of polypeptides that display “e” antigenicity.

During the replication cycle of hepatitis B virus (HBV), three major viral antigens, termed core antigen, surface antigen and “e” antigen, are produced. The core antigen is a conformational antigenic determinant displayed by the viral core protein, and the surface antigen represents the antigenic determinants displayed by the three viral envelope proteins. It has been used as the synonym for HBV envelope proteins. The core protein expressed this way will self assemble into core particles that display core antigenicity. In contrast, the expression of the pre-core protein ORF will result in the secretion of a heterogeneous population of polypeptides that display “e” antigenicity.

While HBeAg antigen has no demonstrated role in the viral replication cycle, the antigen has long been a key clinical marker for viral replication, infectivity, disease severity, and response to treatment.

NAME
Hbeag
DESCRIPTION
e antigen that comprises the 10 aa pre-core sequence plus the 149-residue assembly core domain
GEN
secuencia pre-núcleo más el dominio central
PURITY
>95% by observation on SDS-PAGE electrophoresis
Formats

Liquid solution or dry powder (lyophilised) in vials of 0.1 mg*, 1 mg and bulk.
*under availability, for liquid format

* Our IVD reagents are provided for research and commercial use in vitro: not for human in vivo or therapeutic use. In addition, we follow a rigorous quality control for each lot.

References of Recombinant antigen HBeAg

RAG0062

SOURCE
E. coli
APPLICATIONS
WB Western Blot, DB: Dot Blot, IE: Indirect ELISA, DE: positive control in Direct ELISA, CLIA: Chemiluminescent immunoassay, LF: Lateral-Flow

Folletos

Videos

Reagent sheet

NAME
HBeAg
DESCRIPTION
e antigen that comprises the 10 aa pre-core sequence plus the 149-residue assembly core domain
PURITY
>95% by observation on SDS-PAGE electrophoresis
Formats

Liquid solution or dry powder (lyophilised) in vials of 0.1 mg*, 1 mg and bulk.
*under availability, for liquid format

* Our IVD reagents are provided for research and commercial use in vitro: not for human in vivo or therapeutic use. In addition, we follow a rigorous quality control for each lot.

Join as a distributor